Little Green Pharma Balans Gezondheid

Financiële gezondheid criteriumcontroles 5/6

Little Green Pharma heeft een totaal eigen vermogen van A$77.3M en een totale schuld van A$3.5M, wat de schuld-eigenvermogensverhouding op 4.5% brengt. De totale activa en totale passiva bedragen respectievelijk A$86.3M en A$9.0M.

Belangrijke informatie

4.5%

Verhouding schuld/eigen vermogen

AU$3.50m

Schuld

Rente dekkingsratio	n/a
Contant	AU$4.97m
Aandelen	AU$77.26m
Totaal verplichtingen	AU$9.03m
Totaal activa	AU$86.29m

Recente financiële gezondheidsupdates

Little Green Pharma (ASX:LGP) Has Debt But No Earnings; Should You Worry?

Mar 05

Recent updates

Improved Revenues Required Before Little Green Pharma Ltd (ASX:LGP) Shares Find Their Feet

Nov 19

The Market Doesn't Like What It Sees From Little Green Pharma Ltd's (ASX:LGP) Revenues Yet As Shares Tumble 27%

Jun 30

Statutory Earnings May Not Be The Best Way To Understand Little Green Pharma's (ASX:LGP) True Position

Sep 06

What Type Of Shareholders Make Up Little Green Pharma Ltd's (ASX:LGP) Share Registry?

Feb 11

Analyse van de financiële positie

Kortlopende schulden: De korte termijn activa ( A$21.5M ) LGP } overtreffen de korte termijn passiva ( A$6.4M ).

Langlopende schulden: De kortetermijnactiva LGP ( A$21.5M ) overtreffen de langetermijnschulden ( A$2.6M ).

Schuld/ eigen vermogen geschiedenis en analyse

Schuldniveau: LGP heeft meer geld in kas dan de totale schuld.

Schuld verminderen: LGP had 5 jaar geleden een negatief eigen vermogen, maar is nu positief en is dus verbeterd.

Balans

Analyse van de cashflow

Voor bedrijven die in het verleden gemiddeld verliesgevend zijn geweest, beoordelen we of ze ten minste 1 jaar kasstroom hebben.

Stabiele cash runway: LGP heeft op basis van de huidige vrije kasstroom voldoende cash runway voor meer dan 3 jaar.

Voorspelling contante baan: Er zijn onvoldoende gegevens om te bepalen of LGP voldoende cash runway heeft als de vrije kasstroom blijft groeien of krimpen op basis van historische percentages.

Little Green Pharma Balans Gezondheid

Financiële gezondheid criteriumcontroles 5/6

Belangrijke informatie

Recente financiële gezondheidsupdates

Little Green Pharma (ASX:LGP) Has Debt But No Earnings; Should You Worry?

Recent updates

Now 23% undervalued

Improved Revenues Required Before Little Green Pharma Ltd (ASX:LGP) Shares Find Their Feet

Now 20% undervalued

Little Green Pharma Ltd, Annual General Meeting, Aug 29, 2024

Little Green Pharma Ltd, Annual General Meeting, Aug 29, 2024

Now 30% undervalued after recent price drop

Now 30% undervalued after recent price drop

Now 30% undervalued after recent price drop

Now 30% undervalued after recent price drop

The Market Doesn't Like What It Sees From Little Green Pharma Ltd's (ASX:LGP) Revenues Yet As Shares Tumble 27%

Now 23% undervalued after recent price drop

Estimating The Fair Value Of Little Green Pharma Ltd (ASX:LGP)

Full year 2024 earnings: EPS misses analyst expectations

Forecast breakeven date pushed back to 2026

Now 24% undervalued after recent price drop

Now 22% undervalued after recent price drop

Little Green Pharma (ASX:LGP) Has Debt But No Earnings; Should You Worry?

New major risk - Financial position

Little Green Pharma Ltd, Annual General Meeting, Feb 21, 2024

First half 2024 earnings released: AU$0.007 loss per share (vs AU$0.004 loss in 1H 2023)

Not Many Are Piling Into Little Green Pharma Ltd (ASX:LGP) Just Yet

Little Green Pharma Limited Announces Australian Clinical Study Finds Medicinal Cannabis Significantly Improves Pain, Quality of Life, Moderate-Severe Anxiety and Depression

Little Green Pharma Announces CEO Changes, Effective 29 August 2023

Full year 2023 earnings released: AU$0.034 loss per share (vs AU$0.10 loss in FY 2022)

Now 20% undervalued after recent price drop

Full year 2023 earnings released: AU$0.034 loss per share (vs AU$0.10 loss in FY 2022)

A Look At The Intrinsic Value Of Little Green Pharma Ltd (ASX:LGP)

Little Green Pharma Ltd, Annual General Meeting, Jan 31, 2023

Little Green Pharma Ltd. Obtains Ethics Approval for its Proposed Multi-Site, Placebo-Controlled Pharmacokinetic and Phase III Efficacy and Safety Trial

Little Green Pharma Ltd Significantly Expands Flower Portfolio

Little Green Pharma Ltd Provides Update on French Trial Extension

Less than half of directors are independent

Little Green Pharma Ltd Appoints Beatriz Vicén Banzo as Non-Executive Director

Little Green Pharma Ltd, Annual General Meeting, Aug 12, 2022

Price target decreased to AU$1.04

Insufficient new directors

Executive Director exercised options to buy AU$1.7m worth of stock.

Insufficient new directors

Insufficient new directors

Little Green Pharma Ltd Secures First Registration for Locally Produced Cannabis Medicine in Denmark

Price target decreased to AU$1.04

Full year 2021 earnings released: EPS AU$0.16 (vs AU$0.073 loss in FY 2020)

Statutory Earnings May Not Be The Best Way To Understand Little Green Pharma's (ASX:LGP) True Position

Full year 2021 earnings released: EPS AU$0.16 (vs AU$0.073 loss in FY 2020)

Little Green Pharma Ltd (ASX:LGP) acquired GACP cultivation and GMP licensed medicinal cannabis asset in Denmark for CAD 20 million.

Little Green Pharma Ltd Receives Firm Purchase Order from Deutsche Medizinalcannabis Gmbh

Little Green Pharma Ltd Delivers First French Shipment

First half 2021 earnings released: EPS AU$0.004 (vs AU$0.077 loss in 1H 2020)

Little Green Pharma Ltd Announces Supply of Medicinal Cannabis Oil Products to Enrolled Patients as Well as Providing Funding for Study Costs for the QUality uality of Life Evaluation STudy

Little Green Pharma Ltd announced that it expects to receive AUD 22.1 million in funding

What Type Of Shareholders Make Up Little Green Pharma Ltd's (ASX:LGP) Share Registry?

Little Green Pharma Ltd Exports First Commercial Shipment

Little Green Pharma Ltd Announces it has Selected Primary Supplier of Medicinal Cannabis Oils for French National Trial of Medicinal Cannabis in Partnership Intsel Chimos

New 90-day high: AU$0.65

Little Green Pharma Ltd Announces TGA's final Decision to Both Down-Schedule Certain Medicinal Cannabidiol Products from Schedule 4 to Schedule 3

New 90-day high: AU$0.61

Little Green Pharma Ltd Provides Update on Its Export of the Largest Australian Commercial Shipment

New 90-day high: AU$0.36

Little Green Pharma Ltd Announces Post-Market Survey Test Results

New 90-day low - AU$0.31

Analyse van de financiële positie

Schuld/ eigen vermogen geschiedenis en analyse

Balans

Analyse van de cashflow

Ontdek gezonde bedrijven